Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy Outcomes in a U.S. Population

Obstet Gynecol. 2021 Aug 9. doi: 10.1097/AOG.0000000000004547. Online ahead of print.ABSTRACTOBJECTIVE: To examine whether the coronavirus disease 2019 (COVID-19) pandemic altered risk of adverse pregnancy-related outcomes and whether there were differences by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection status among pregnant women.METHODS: In this retrospective cohort study using Epic's Cosmos research platform, women who delivered during the pandemic (March-December 2020) were compared with those who delivered prepandemic (matched months 2017-2019). Within the pandemic epoch, those who tested positive for SARS-CoV-2 infection were compared with those with negative test results or no SARS-CoV-2 diagnosis. Comparisons were performed using standardized differences, with a value greater than 0.1 indicating meaningful differences between groups.RESULTS: Among 838,489 women (225,225 who delivered during the pandemic), baseline characteristics were similar between epochs. There were no significant differences in adverse pregnancy outcomes between epochs (standardized difference
Source: Obstetrics and Gynecology - Category: OBGYN Authors: Source Type: research

Related Links:

This study evaluated the proportion and the maternal and neonatal outcomes associated with SARS-CoV-2 infection among pregnant women with comorbidities. Participants were recruited consecutively in order of admission to a maternity for pregnant women with comorbidities. Sociodemographic, clinical, and laboratory data were prospectively collected during hospitalization. Pregnant women were screened at entry: nasopharyngeal swabs were tested by RT-PCR; serum samples were tested for IgG antibodies against spike protein by ELISA. From April to June 2020, 115 eligible women were included in the study. The proportion of SARS-CoV...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson &Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson &Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
The coronavirus pandemic has had long lasting implications for everyone worldwide. For those pregnant, attempting pregnancy, or pursuing fertility treatment, there are many new questions to be considered, and answers can vary by region and situation. The vaccines available in the US for protection against the SARS-CoV-2 virus that causes COVID-19- produced by Pfizer, Moderna, and Johnson &Johnson, have not been specifically tested for safety in pregnancy. For drug trials to deliberately include pregnant women is ethically complicated, as we want to avoid any remote possibility of causing harm to the pregnancy or the in...
Source: Cord Blood News - Category: Perinatology & Neonatology Authors: Tags: Cord Blood medical research pregnancy safety vaccines Source Type: blogs
More News: Coronavirus | COVID-19 | Eating Disorders & Weight Management | Insurance | Obesity | OBGYN | Pandemics | Pregnancy | Respiratory Medicine | SARS | Study | Women